2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176921
    ONO-2570366
    ONO-2570366 (Compound 11a) is an antagonist of the cysteinyl leukotriene receptors CysLT1R and CysLT2R (IC50 = 14 nM). ONO-2570366 inhibits the binding of LTD4
    ONO-2570366
  • HY-176979
    CCR6 antagonist 3 98%
    CCR6 antagonist 3 (compound OXM2) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 166 nM). CCR6 antagonist 3 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 3 can be used for chronic inflammatory diseases research.
    CCR6 antagonist 3
  • HY-176980
    CCR6 antagonist 4 98%
    CCR6 antagonist 4 (compound OXM1) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 158 nM). CCR6 antagonist 4 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 4 can be used for chronic inflammatory diseases research.
    CCR6 antagonist 4
  • HY-176994
    3-Et-3TC 1995864-98-6 98%
    3-Et-3TC (Page 87, Compound 3b) is a structurally modified derivative of Lamivudine (HY-B0250). 3-Et-3TC can inhibit the activation of the NLRP3 inflammasome and can be used for the study of retinal degenerative diseases.
    3-Et-3TC
  • HY-177058
    DSP30
    DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL).
    DSP30
  • HY-177075
    Crovozalpon 2406205-67-0 98%
    Crovozalpon (Compound 4) is an inhibitor of alplha-1-antitrypsin. Crovozalpon can be used as a prodrug. Crovozalpon can be studied in research for diseases associated with alplha-1-antitrypsin
    Crovozalpon
  • HY-177274
    Antimitotic agent-2 182878-97-3
    Antimitotic agent-2 (Compound 1) is an antimitotic agent. Antimitotic agent-2 inhibits the proliferation of human epidermal cells. Antimitotic agent-2 can be used in hyperproliferative skin disorders.
    Antimitotic agent-2
  • HY-177282
    SST1 receptor antagonist-2 524743-70-2
    SST1 receptor antagonist-2 (Example 2) is a piperazine derivative and a somatostatin receptor 1 (SST1) antagonist. SST1 receptor antagonist-2 can be used in the research of psychiatric diseases, neurodegenerative diseases, tumors, as well as vascular disorders and immunological diseases.
    SST1 receptor antagonist-2
  • HY-177300
    TLR7/8 agonist 13 1402802-45-2 98%
    TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus.
    TLR7/8 agonist 13
  • HY-177406
    VR11 aptamer
    VR11 aptamer is a DNA-based TNF-α inhibitor with a KD of 7.0 nM. VR11 aptamer prevents TNFα-induced apoptosis and NO production. VR11 aptamer has non-immunogenicity and does not raise immune responses when injected intraperitoneally into C57BL/6 mice model. VR11 aptamer can be used for inflammatory diseases research.
    VR11 aptamer
  • HY-177447
    Human NLRP3 mRNA
    Human NLRP3 mRNA encodes the human NLRP3 protein, an inflammasome. NLRP3 belongs to the NLR protein family and plays a crucial role in immunity and human disease.
    Human NLRP3 mRNA
  • HY-177500
    RGH 5702 136499-29-1 98%
    RGH 5702 is a new mucosal mast cell protector, antiulcer agent.
    RGH 5702
  • HY-177557
    IDO-IN-19 2033173-20-3 98%
    IDO-IN-19 (Compound I) is a free base of an imidazole-isoindole derivative. IDO-IN-19 can inhibit the activity of Indoleamine 2,3-Dioxygenase (IDO). IDO-IN-19 can block the decomposition of tryptophan and restore the function of T cells. IDO-IN-19 can be used for the researches of cancer, immunology, infection and neurological disease, such as breast cancer and Alzheimer's disease.
    IDO-IN-19
  • HY-177608
    Rat IL10 mRNA 98%
    Rat IL-10 mRNA encodes interleukin-10 (IL-10). IL-10 is expressed in tissues/cells such as hepatic stellate cells and is involved in physiological processes including liver fibrosis.
    Rat IL10 mRNA
  • HY-177933
    mNOX-E36 98%
    mNOX-E36 is a murine-specific analogue of NOX-E36 (HY-148100), an anti-CCL-2 L-RNA aptamer that binds and neutralises the mouse chemokine CCL-2. mNOX-E36 reduces scarring in an experimental murine model of glaucoma filtration surgery (GFS). mNOX-E36 ameliorates lupus nephritis in mice. mNOX-E36 can be used for GFS and lupus nephritis research.
    mNOX-E36
  • HY-178853
    3,4-Dihydroxybenzeneethanimidamide 87112-04-7
    3,4-Dihydroxybenzeneethanimidamide can selectively react with Gly-Pro, the substrate for prolidase, and the prolidase activity is measured by monitoring the decrease in FL intensities. 3,4-Dihydroxybenzeneethanimidamide can be used for the study of inflammation.
    3,4-Dihydroxybenzeneethanimidamide
  • HY-178912
    Anti-MRSA agent 39
    Anti-MRSA agent 39 is an orally active ClpX modulator that binds Staphylococcus aureus caseinolytic protease X (SaClpX) with high affinity (Kd = 3.6 μM). Anti-MRSA agent 39 exerts antibacterial effects through temperature-dependent inhibition of cell division. Anti-MRSA agent 39 elicits profound metabolic dysregulation in methicillin-resistant Staphylococcus aureus (MRSA), manifesting as significantly reduced ATP levels, elevated reactive oxygen species (ROS), and decreased NAD+/NADH ratio, and accelerates bacterial lysis rates in MRSA ATCC 33591. Anti-MRSA agent 39 significantly increases the proportion of MRSA cells in the mitotic phase, and the cells exhibit obvious morphological abnormalities. Anti-MRSA agent 39 can be used for the study of invasive MRSA infections.
    Anti-MRSA agent 39
  • HY-179444
    Antituberculosis agent-17
    Antituberculosis agent-17 (compound 21) is a potent and selective antituberculosis agent. Antituberculosis agent-17 displays excellent anti-Tuberculosis (TB) activity against H37Rv, MDR and XDR strains of TB (MIC = 0.2-0.78 μM). Antituberculosis agent-17 exhibits selectivity for Mycobacterium tuberculosis over selected non-TB forming mycobacteria and bacteria. Antituberculosis agent-17 can be used for TB research.
    Antituberculosis agent-17
  • HY-179532
    Antimycobacterial agent-14
    Antimycobacterial agent-14 (compound 20s) is an antimycobacterial agent with potent activity against Mycobacterium tuberculosis (M.tb) H37Ra strain with a MIC of 11.37 μM. Antimycobacterial agent-14 can be used for tuberculosis (TB) research.
    Antimycobacterial agent-14
  • HY-179802
    C20:0 GM1 Ganglioside ammonium 2456349-05-4 98%
    C20:0 GM1 Ganglioside (ammonium) is a glycosphingolipid.
    C20:0 GM1 Ganglioside ammonium
Cat. No. Product Name / Synonyms Application Reactivity